FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.
'Earnings revival could be two quarters away.'
Benchmark Sensex and Nifty after gaining nearly 30% in 2014 are trading in negative this year
Telcos have indicated that rates will have to be raised, as higher volumes alone will not suffice to meet the higher costs.
Market experts believe the retreat is because of uncertainty.
The challenge of merging Ranbaxy into the company has not been factored in.
India is its second-biggest market in terms of geographical presence
If companies manage to raise Rs 10,000 crore, this will be the best year for IPOs since FY11.
It was a year of big gains for equity investors.
Given the better growth in JLR sales and improving domestic sales, nearly 90 per cent of the analysts covering the stock have a 'Buy' rating.
Asset managers are betting big on ETFs these days.
Sun Pharma's Dilip Shanghvi is India's richest person.
BJP loss could trigger a correction
.jpg)
CIL aims to sell 12.6 mn shares to retail investors
After his previous visit, the Sensex crashed and it took four painful years to top the 21,000 mark.
Half of the sharp rise in stocks in 2014 was driven by re-ratings - rise in price-to-earning ratios on hopes the new government would turn around the economy which will reflect in corporate earnings.
Maruti has improved its sales in the recent past.
Benchmark indices gain 30% this year, buoyed by global liquidity, new government
Have a Plan B in place if the tide turns against you.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances